Literature DB >> 2883635

Immunohistochemical studies for multiple peptide-immunoreactivities and co-localization of Met-enkephalin-Arg6-Gly7-Leu8, neuropeptide Y and somatostatin in human adrenal medulla and pheochromocytomas.

R Y Osamura, Y Tsutsumi, N Yanaihara, H Imura, K Watanabe.   

Abstract

Three normal human adult adrenal medullas and 12 cases of pheochromocytomas were studied for immunohistochemical localization of various peptides. Met-enkephalin-Arg6-Gly7-Leu8 (MEAGL) was present in all cases of pheochromocytomas. The normal adrenal medulla showed cells immunoreactive for MEAGL, neuropeptide tyrosine (NPY) and proopiomelanocortin derived N-terminal fragment (NTF). MEAGL and NPY were co-localized in some adrenal medullary cells. Pheochromocytomas showed striking multiple immunoreactivities regardless of histologic types, pleomorphic or organoid. Ten cases showed immunoreactivities for more than two peptides. All cases showed immunoreactivity for MEAGL and 9 cases showed NPY positive cells. Some tumor cells contain both MEAGL and NPY in the cytoplasm. Six cases were positive for somatostatin. Some tumor cells were shown to contain both MEAGL and SS. The appearance of SS and other peptides was considered to be related to the neoplastic transformation of the adrenal medulla.

Entities:  

Mesh:

Substances:

Year:  1987        PMID: 2883635     DOI: 10.1016/0196-9781(87)90168-9

Source DB:  PubMed          Journal:  Peptides        ISSN: 0196-9781            Impact factor:   3.750


  2 in total

1.  Paraganglial cells of urinary bladder and prostate: potential diagnostic problem.

Authors:  J Rode; A Bentley; C Parkinson
Journal:  J Clin Pathol       Date:  1990-01       Impact factor: 3.411

2.  Distinct morphological and immunohistochemical features and different growth rates among four human neuroblastomas heterotransplanted into nude mice.

Authors:  Nobuo Hoshi; Jiro Hitomi; Takashi Kusakabe; Takeaki Fukuda; Masayuki Hirota; Toshimitsu Suzuki
Journal:  Med Mol Morphol       Date:  2008-09-20       Impact factor: 2.309

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.